AstraZeneca And Merck Present Final Results Of Key Secondary Overall Survival Endpoint From Phase III Propel Trial At ASCO GU Cancers Symposium
February 18, 2023
February 18, 2023
WILMINGTON, Delaware, Feb. 18 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release on Feb. 16, 2023:
* * *
Results showed an absolute difference of an additional 7.4 months in median overall survival for LYNPARZA(R) (olaparib) plus abiraterone in this setting vs. abiraterone alone
* * *
Results from the final prespecified overall survival (OS) analysis of the PROpel Phase III trial in metastatic castration-res . . .
* * *
Results showed an absolute difference of an additional 7.4 months in median overall survival for LYNPARZA(R) (olaparib) plus abiraterone in this setting vs. abiraterone alone
* * *
Results from the final prespecified overall survival (OS) analysis of the PROpel Phase III trial in metastatic castration-res . . .